Reports Q2 revenue $19.08M, consensus $18.69M. “Q2 2025 was a milestone quarter for Paysign (PAYS),” said Mark Newcomer, President and CEO of Paysign. “We achieved record quarterly revenue of $19.1 million, expanded gross margins and more than doubled adjusted EBITDA to $4.5 million versus the same period last year. Net income rose 99% to $1.4 million, even after absorbing approximately $300,000 in one-time expenses tied to the late-quarter onboarding of 123 plasma centers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Paysign price target raised to $8-$9 range at Barrington
- Strategic Positioning and Growth Potential: PaySign’s Role in Pharmaceutical Patient Affordability
- Paysign price target raised to $9 from $7 at Lake Street
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call